- Healthgen Announces Listing on October 28, 2025 On the morning of October 28, 2025, Wuhan Healthgen Biotechnology Corp. (Stock Name: Healthgen Biotech; Stock Code: 688765) was officially listed on the Shanghai Stock Exchange, marking its status as the first listed company specializing in recombinant human albumin. Found... Posted by Site editor|2025-10-28 LearnMore
- The authoritative international hepatology journal Gut published a commentary highlighting the significant clinical implications of Recombinant Human Albumin Injection (Oryza Sativa)in albumin therapy The official journal of the British Society of Gastroenterology, Gut (Impact Factor 25.8), recently published an in-depth commentary by Professor Rajiv Jalan of University College London and Professor Paolo Caraceni of the University of Bologna. The article provides an in-depth a... Posted by Site editor|2025-07-31 LearnMore
- Recombinant Human Albumin Injection (Oryza Sativa) receives approval to initiate Phase III Clinical Trials in the United States Recently, Healthgen’s proprietary, first-in-class drug, Recombinant Human Albumin Injection (Oryza Sativa), successfully has successfully completed a Type C meeting with the U.S. FDA. During the meeting, Healthgen reached a consensus on international multicenter Phase ... Posted by Site editor|2025-08-08 LearnMore
- Recombinant Human Albumin(Oryza sativa) Selected into List of Landmark Biomanufacturing Products by the Ministry of Industry and Information Technology of the People's Republic of China On July 31, 2025, the Ministry of Industry and Information Technology of the People's Republic of China announced the first batch list of landmark biomanufacturing products list for 2024. A total of 36 landmark products cover multiple sub-fields such as bi... Posted by Site editor|2025-08-07 LearnMore
- Clinical Trial Data of Recombinant Human Albumin Injection (Oryza Sativa) was published in the journal "Gut" Recently, the R&D team of Healthgen has published groundbreaking research in GUT, a premier journal in gastroenterology and hepatology (Impact Factor: 25.8). The paper, titled "Rice-derived recombinant human serum albumin as an alternative to human plasma ... Posted by Site editor|2025-06-26 LearnMore
Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3
